Market Trends of North America Mammography Industry
The Digital Mammography Segment is Expected to Account for the Largest Market Share During the Forecast Period
Digital mammography is a specialized and advanced form of mammography that uses digital receptors and computers instead of X-ray films to examine breast tissue for the presence of tumors. The shifts toward these newer systems are due to their superior depiction of low-contrast objects, wider dynamic change, and improved diagnostic quality of images, especially when examining denser breasts. They also come with the added advantage of soft-copy image displays and soft-copy reading, which can be easily transferred. Radiation exposure is significantly lower as compared to analog systems. The increasing burden of breast cancer in the region and growing healthcare expenditure is propelling the end-user to replace the conventional systems with the most advanced systems in the region.
For instance, according to the data from the American Cancer Society in 2022, it is estimated that about 13% or 1 in 8 of women in the United States women are going to develop invasive breast cancer during the course of their life, and an estimated 51,400 new cases of non-invasive (in situ) breast cancer in 2022 is expected to be diagnosed in American women. According to the same source, a man's lifetime risk of developing breast cancer is about 1 in 833. Hence, the high prevalence of breast cancer in the region is expected to enhance the segment growth during the forecast period of the study.
Furthermore, continuous product launches by major players in the market are positively affecting the growth of the segment. For instance, in March 2021, DRTECH launched three new innovative products for general radiography and mammography imaging, AIDIA; a premium full-field digital mammography system, QX Platform; high-performance IGZO low dose detector, and the EXSYS Essence; a compact but powerful X-ray system for general radiography.
Therefore, the digital mammography segment is expected to witness significant growth over the forecast period due to the abovementioned factors.
The United States is Expected to Hold a Significant Market Share During the Forecast Period
The United States has been the hub of all major research and development activities related to mammography for many years due to its advanced healthcare and clinical trial infrastructure. Furthermore, the rising prevalence of breast cancer and the rising healthcare expenditure in the country are some of the major factors driving the growth of the market.
The rising prevalence of breast cancer in the United States is one of the major factors that is increasing the demand for mammography tests in the country. For instance, according to data from Breastcancer.org published in January 2022, there are more than 3.8 million women living with a history of breast cancer in the United States, and this includes women who are currently being treated and women who have finished treatment. The source also claims that breast cancer is the most commonly diagnosed cancer among American women and in 2022 it is estimated that about 30% of newly diagnosed cancers in women are going to be breast cancers.
Furthermore, various product launches by major players in the country are contributing to the growth of the segment. For instance, in October 2021, Delphinus Medical Technologies, Inc. announced that the United States FDA has granted premarket approval (PMA) for its SoftVue 3D Whole Breast Ultrasound Tomography System (SoftVue) for use as an adjunct to digital mammography in the screening of asymptomatic women with dense breast tissue.
Hence, due to the aforementioned factor the United States is expected to have significant growth in the studied market.
